Pacifica Silver Corp. held its annual general meeting where all resolutions were approved, including the re-election of directors and appointment of auditors. Following the meeting, Alan Tam resigned as CFO and director, with Israel Munoz appointed as the new CFO and Karenn Ramirez joining the board as a director. Both bring extensive mining finance and governance experience, supporting the company's growth and the advancement of its Claudia Silver-Gold Project in Mexico. The company also granted stock options to the new appointees as part of their incentive plan.
Pacifica Silver's recent AGM and leadership changes provide context for readers following mining and basic materials. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Sep 15, 2026 03:11 WIB: out of 32 priced US stocks, only 1 rose while 31 fell. AngloGold Ashanti Limited (AU) was down 4.12% at USD 100.12, Vale SA (VALE) dropped 3.55% to USD 14.69, and Kinross Gold Corporation (KGC) declined 3.36% to USD 28.15.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
